Levity on Instagram: "Pancreatitis headlines around GLP-1s can sound alarming, but the data tells a much calmer story 🎉 In a large U.S. study following nearly 1 million people with type 2 diabetes for up to five years, researchers compared those taking GLP-1 receptor agonists (including liraglutide) with those who weren’t. The result? No increased risk of pancreatitis. Incidence remained very low in both groups (~0.1–0.4%), with the lifetime risk actually slightly lower in GLP-1 users (0.3% vs.